|Krzysztof Kowal, Irena Złotnik, Joanna Osada, Milena D±browska, Anna Bodzenta-Łukaszyk|
The aim of this study was to evaluate expression of selected surface antigens on peripheral blood monocytes in bronchial asthma patients during exacerbation treated with oral prednisone 40 mg/day. Eight patients with moderate asthma (mean FEV1 = 63.3%±12%) were studied. Five healthy persons were negative controls. All asthma patients had positive skin prick tests to Dermatophagoides pteronyssinus. During exacerbation, short course of oral corticosteroids was introduced. Blood samples were collected before corticosteroid therapy, 24 hours and 5 days after the therapy was started. Flow cytometry analysis using labeled monoclonal antibodies to CD14, CD16, CD36, was performed on the whole blood. In comparison with healthy controls, in asthma patients, during exacerbation, higher percentages of cells expressing CD14+, CD16+, and CD14+/CD16+ in peripheral blood monocyte population were detected (65.1±16.4% vs. 90.5±2.9%; 29.7±14% vs. 54.3±11.9%; 5.4±7% vs. 45±12.1%, respectively). After five days of the therapy, significant clinical improvement was noted and it correlated with lung function test results (mean FEV1=76%±8.3%). At that time, significant decrease in the percentage of CD14+ (80.4±4.5%) and CD36+ (58.8±14.3%) was found, but the percentage of CD14+ cells was still higher than in healthy controls. The percentage of CD14+/CD16+ cells after 5 days of therapy remained high (54.8±11.2%).
Significant changes in peripheral blood monocyte subpopulations occur in patients with asthma exacerbation treated with short course of oral prednisone.
Alergia Astma Immunologia, 2001, 6(1), 39-43
keywords: monocyty, dychawica oskrzelowa, kortykosteroidy, monocytes, bronchial asthma, corticosteroids
pages: from 39 to 43
|estimated time of download (79 kB)|